Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announce Filing of Supplemental New Drug Application for AMITIZA (Lubiprostone) in Opioid-induced Constipation  
7/27/2012 9:45:44 AM

BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A. Inc. (TPUSA) today announced the filing of a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for a new indication for AMITIZA® (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.